Editor's Corner
Remembering Kristin Hubing
August 2022
Mikkael Sekeres, MD, David Steensma, MD, and Aaron Gerds, MD
On July 8, 2022, our managing editor for ASH Clinical News, Kristin Hubing, left this earth at a devastatingly young age for what we hope is a more joyous place. She left behind her husband Kyle and her infant son Theo, along with scores of family, friends, and her work family at ASH. Her death leaves a huge hole in all our hearts.
NEWS
Advertisement
Most Read Articles
- AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation
- High-Precision, Allogeneic Cell Therapy Improves Survival in Patients With Hematologic Malignancies
- Venetoclax Combination Therapy Works Better in Some AML Subtypes Than Others
- SRSF2 Mutation Status May Predict Romiplostim Treatment Response in Lower-Risk MDS
- Nilotinib Demonstrates Greater Efficacy Than Imatinib in CML
Advertisement
From the Desk Of...
August 2022
Dr. Gerds shares his thoughts on the August issue including the relevance of the feature story on marijuana, the link between lenalidomide and the risk of therapy-related myeloid neoplasms, and more.
Immune Response Muted in Patients With NHL/CLL Who Are Vaccinated Against COVID-19
August 2022
A study published in Journal of Clinical Oncology found that such patients’ antibody binding and neutralization against the original SARS-CoV-2 virus and variants such as Delta and Omicron were substantially lower compared to healthy vaccinees.
Lenalidomide Linked to Risk of Therapy-Related Myeloid Neoplasms
August 2022
“Our result might offer a personalized approach to reducing the risk of t-MNs,” said study researcher Koichi Takahashi, MD, PhD, of the University of Texas MD Anderson Cancer Center.